A method of treating acute myeloid leukemia
AssigneeAgency for Science, Technology and Research
InventorsAmit Singhal, Kumar Dilip
Life of this patent
Estimating the term…
Abstract
There is provided a genetically modified cell wherein at least one gene has been deleted from the cell and the gene is selected from the group consisting of p50, p52, p65, c-Rel, and RelB. Also disclosed are methods of identifying a target for treating acute myeloid leukemia (AML) in a subject, methods of treating acute myeloid leukemia (AML) in a subject in need thereof, comprising inhibiting the activity of an NF-KB pathway. Also provided is an ATP13A2 inhibiting agent for use in therapy or medicine, for use in treating AML, and in the manufacture of a medicament for treating AML.
Claims19
A genetically modified cell wherein at least one gene has been deleted from the cell and the gene is selected from the group consisting of p65 (RELA), p50 (NFKB1), p52 (NFKB2), c-Rel (REL), and RelB (RELB).
A method of identifying a therapeutic target for treating acute myeloid leukemia (AML) in a subject, the method comprising
- providing a genetically modified cell wherein at least one gene has been deleted from the cell and the gene is selected from the group consisting of p65 (RELA), p50 (NFKB1), p52 (NFKB2), c-Rel (REL), and RelB (RELB).
A method of treating acute myeloid leukemia (AML) in a subject in need thereof, comprising modulating the activity of an NF-KB pathway.
-21. (canceled)
Dependencies are inferred from the claim text.